HomeADVM • NASDAQ
add
Adverum Biotechnologies Inc
Previous close
$2.58
Day range
$2.34 - $2.60
Year range
$1.78 - $10.14
Market cap
52.02M USD
Avg Volume
286.87K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 19.47M | 41.23% |
Net income | -47.02M | -73.20% |
Net profit margin | — | — |
Earnings per share | -2.25 | -50.00% |
EBITDA | -47.54M | -68.56% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 83.08M | -57.02% |
Total assets | 137.65M | -48.60% |
Total liabilities | 111.23M | 30.04% |
Total equity | 26.42M | — |
Shares outstanding | 20.89M | — |
Price to book | 2.05 | — |
Return on assets | -75.94% | — |
Return on capital | -85.49% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -47.02M | -73.20% |
Cash from operations | -42.77M | -84.00% |
Cash from investing | 31.28M | 242.01% |
Cash from financing | — | — |
Net change in cash | -11.49M | -115.40% |
Free cash flow | -27.04M | -67.12% |
About
Adverum Biotechnologies, Inc., formerly known as Avalanche Biotechnologies, is a publicly traded clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration. Wikipedia
Founded
Jan 1, 2006
Headquarters
Website
Employees
155
